Deal facts
- Buyer
- BC PARTNERS
- Target
- BIOGARAN
- Deal value
- Not disclosed
- Announced
- 19 October 2025
- Status
- In review
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- Not stated
Sources
BC PARTNERS has agreed to acquire BIOGARAN in a transaction announced on 19 October 2025. The deal involves the French pharmaceutical distributor operating within the wholesale of pharmaceutical goods sector. No financial terms or specific consideration structure have been disclosed to the public at this stage. The transaction is currently subject to regulatory approval and remains in the review phase.
The acquisition marks a significant development for BIOGARAN as it transitions under new ownership. BC PARTNERS will assume full control of the business operations following the completion of all necessary regulatory checks. While the exact valuation remains undisclosed, the deal represents a strategic shift for the target company. The transaction is expected to proceed once all regulatory conditions are satisfied by the relevant authorities.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CMA invitation to comment
BC PARTNERS to acquire BIOGARAN
BC PARTNERS to acquire BIOGARAN
EU DG COMP
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS
KOHLBERG / MONTAGU has agreed to acquire the TELEFLEX OEM Business in a transaction announced on 22 March 2026. The deal involves a company operating within the NaceV2Se…
- Buyer
- KOHLBERG / MONTAGU
- Target
- TELEFLEX OEM BUSINESS
- Deal value
- Not disclosed
- Deal type
- unknown
SK CAPITAL to acquire SWIXX BIOPHARMA
SK CAPITAL has agreed to acquire SWIXX BIOPHARMA in a transaction announced on 8 March 2026. The deal involves the biopharmaceutical sector, specifically within the whol…
- Buyer
- SK CAPITAL
- Target
- SWIXX BIOPHARMA
- Deal value
- Not disclosed
- Deal type
- unknown
EQT to acquire Oxford Biomedica plc
EQT has agreed to acquire Oxford Biomedica plc, a UK-based CDMO and viral vector specialist, in a transaction announced on 25 February 2026. The specific financial terms…
- Buyer
- EQT
- Target
- Oxford Biomedica plc
- Deal value
- Not disclosed
- Deal type
- unknown
GTCR to acquire ZENTIVA
GTCR has agreed to acquire ZENTIVA in a transaction announced on 19 February 2026. The deal involves the pharmaceutical sector, classified under NaceV2Sector_C_21. No fi…
- Buyer
- GTCR
- Target
- ZENTIVA
- Deal value
- Not disclosed
- Deal type
- unknown
WARBURG PINCUS to acquire SEBIA
WARBURG PINCUS has agreed to acquire SEBIA in a transaction announced on 12 November 2025. The deal involves a company operating across multiple industrial sectors, incl…
- Buyer
- WARBURG PINCUS
- Target
- SEBIA
- Deal value
- Not disclosed
- Deal type
- unknown
Buyer history
BC PARTNERS
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive